TLR7 and neoplasm: TLR7/8 agonist nanoparticles triggered DC activation and expansion, leading to expansion of antigen specific CD8+ T cells and enhanced CTL response, which resulted in significant prophylactic and therapeutic efficacy in melanoma, bladder, and renal cell carcinoma tumor models [110].